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Human embryonic stem cells have been characterized as a rare and precious resource because of the scar-
city of the materials used in their creation and the many restrictions that have been placed on their derivation
and use.With the advent of induced pluripotent stem cells, however, pluripotency stands to become a plenti-
ful and unencumbered commodity.The first cultured cells that were shown to
exhibit pluripotency were embryonal
carcinoma cells, through studies arising
directly from the work of Leroy Stevens
with teratomas (meaning ‘‘monstrous
tumors’’) in mouse. It was nearly 15 years
before the first reports of a nonmalignant
pluripotent cell appeared in the form of
mouse embryonic stem cells (ESCs), and
more than 15 years again before Thomson
et al. derived the first human ESCs (see
Andrews [2002] for a review of the early
history of pluripotency).
Despite tracing their heritage back to
a monster, human ESCs (hESCs) were
recognized immediately as a precious
biological resource. Their perceived value
stemmed from fundamental scientific
interest, as well as their tremendous ther-
apeutic promise, should their capacity for
differentiation, self-renewal, and prolifera-
tion be harnessed for regenerative medi-
cine applications. ESCs were also
deemed precious, however, because
they were rare. The finite number of avail-
able lines was not only because of the
scarcity of their biological source, the
inner cell mass of a preimplantation
embryo, and the low efficiency of early
derivation procedures but also subse-
quently because of the ethically charged
nature of that source, which resulted in
restrictions being placed on the freedom
of scientists in some countries to generate
and/or study them and of funding
agencies to support such research. The
combination of these biological, tech-
nical, political, religious, and ethical
factors militated against the unfettered
development of hESC research as a glob-
ally inclusive field, to the extent that only
a few hundred hESC lines have been es-
tablished in the decade since their original360 Cell Stem Cell 5, October 2, 2009 ª2009derivation, and only a tiny number of
those lines are in active use even today
(Scott et al., 2009).
At the same time that many groups
were seeking a noncontroversial alternate
source of pluripotent human cells,
multiple labs reported the establishment
of human induced pluripotent stem cells
(iPSCs) in 2007, following on the pioneer-
ing work by Takahashi and Yamanaka,
who established the first murine iPSC
lines the previous year (reviewed in Yama-
naka, 2009). Although this research was
not primarily motivated by the desire to
work around restrictive hESC regulations,
the generation of iPSCs was hailed by
many as a solution to the ethical chal-
lenges faced by hESC researchers. Now,
the rapid development of diverse safer
and more efficient methods for deriving
human iPSCs, combined with the
extremely diverse and readily available
cell types from which they can be gener-
ated, stands to change how we think
about pluripotency in human cells. Specif-
ically, pluripotent cells were first consid-
ered a precious and (in practical
terms) scarce resource and have now
become a plentiful, theoretically limitless,
commodity. Importantly, by increasing
access to, or supply of, usable pluripotent
cells, this form of commodification brings
about a decrease in the value of any indi-
vidual source or instance of pluripotency,
and simultaneously elevates the value of
pluripotency, as an accessible research
and potential therapeutic construct, in
more general terms. As has been seen in
other technological breakthroughs, such
as computational power or gene
sequencing, the calculus of value may
quickly shift from one of restricted avail-
ability and correspondingly high unit valueElsevier Inc.to one in which the opposite relationship
prevails. The implications of this change
are profound, not only in terms of the
scientific usage of such cells but also in
terms of the ethical, legal, and social
issues that surround their use as well.
The commodification of pluripotency by
the arrival of iPSCs has not entirely diluted
the value of the ESC, which is still gener-
ally held to be the ‘‘gold standard’’ by
which all pluripotency should be judged,
given their ability to give rise to live
offspring via tetraploid complementation
(in mice) and to form teratomas on trans-
plantation into a living mouse (for hESCs).
Furthermore, the processes underlying
the generation of iPSCs remain relatively
poorly understood, and without side-by-
side study with ESCs, it is unlikely that
the field will tease apart the detailed
mechanisms that regulate pluripotency.
In an influential review, Maherali and Ho-
chedlinger suggested that iPSCs should
be evaluated for pluripotency in accor-
dance with a previously developed hier-
archy of criteria, beginning with in vitro
differentiation and ending with (for mouse
ESCs) tetraploid complementation (Ma-
herali and Hochedlinger, 2008). Recog-
nizing that for technical and ethical
reasons not all of these tests could be
performed on human iPSCs, the authors
allowed that proof of authenticity be
made by the ‘‘highest-stringency test
available.’’
This proposed allowance triggered a
pair of opposing responses from groups
of pluripotent stem cell researchers. The
first expressed concern over the potential
for misidentification of nonpluripotent cell
colonies as iPSCs and favored a strict
interpretation of pluripotency (Daley
et al., 2009), whereas the second group
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cases be acceptable (Ellis et al., 2009).
Interestingly, two of the major reasons
for the loose standards group’s recom-
mendation were that strictu sensu pluri-
potency is not also the most important
determinant of value, and that, ‘‘for iPS
technology to have its most profound
impact, it is important to simplify the
entrance requirements’’ in order to allow
more labs to enter the field (Ellis et al.,
2009). Although it is arguable that the
distinction is a semantic one, this
perspective seems to signal a shift, in at
least some of the scientific community,
from valuing pluripotent cells simply for
the fact that they are pluripotent to valuing
them for a subset of the things they can
do. This growing paradigm shift is partic-
ularly evident given that both the Daley
and Ellis letters acknowledged that tera-
toma formation (a hallmark of pluripo-
tency) is a decidedly undesirable feature
of otherwise highly differentiative cells if
used in clinical applications (Daley et al.,
2009; Ellis et al., 2009). This caveat in no
way tarnishes the luster of the gold stan-
dard of pluripotency, only suggests
a change in perception that may lead to
more researchers approaching pluripo-
tency as a useful starting point, rather
than an object of study itself. Granted,
the findings that extant iPSCs from
different sources show highly variable
tumorigenicity (Miura et al., 2009) and
significant differences in gene expression
from hESCs (Chin et al., 2009) highlight
the need for further study, but these prop-
erties are unlikely to signal a retreat back
into the arms of hESCs for labs concerned
with future applications.
Commodification has brought democ-
ratization as well. This result is clear given
the significant contributions to the study
of iPSCs made by individual labs that for
legal or funding-related reasons may
have been precluded from working with
hESCs. The broadened access to pluripo-
tent stem cells is not simply the result of
relaxed criteria; it is also due to their ethi-
cally uncomplicated source. iPSCs,
famed for leveling out the ‘‘epigenetic
landscape,’’ have, from at least some
perspectives, effectively leveled the regu-
latory landscape as well. That said, the
ISSCR continues to call for their ‘‘Guide-
lines for the Conduct of Human Embry-
onic Stem Cell Research’’ to be applied
‘‘to the use of human totipotent or plurip-otent cells or human pluripotent stem cell
lines’’ in general (in section 4, ‘‘Scope of
the Guidelines’’), and it is possible that
stem cell research organizations or other
regulatory bodies may seek to extend
the cumbersome rules originally designed
to govern research using human embryos
to the oversight of human pluripotent
stem cells as a whole.
Importantly, although the former U.S.
President’s Council on Bioethics declared
the then still-speculative ‘‘de-differenti-
ated somatic cells’’ as ‘‘nothing to object
to ethically,’’ (PCBE, 2005) it is unlikely
that iPSCs will be entirely free of ethical
problems as they become more widely
accessible. In their excellent review,
Aalto-Seta¨la¨ et al. propose changes to
the donor consent requirements that
may be required when collecting somatic
cells to transform to pluripotency, given
the potentially expanded possibilities for
use in genetic modification, human-
animal chimerism, genome sequencing,
and commercialization, as well as in
medical and reproductive applications
(Aalto-Seta¨la¨ et al., 2009). The potential
for human iPSCs to be used in germline
differentiation and reproductive applica-
tions is perhaps the most ethically fraught
of these possibilities. Japan initially went
so far as to ban experiments intended to
differentiate human pluripotent stem cells
into the germ lineage, although these
restrictions have subsequently been
relaxed. The demonstration that iPSCs
can give rise to live mice through tetra-
ploid complementation opens up the
further possibility of reproductive cloning
(Zhao et al., 2009; Kang et al., 2009).
Although this technique has never
successfully been used with human cells
(which would also be illegal in many coun-
tries), the past record of putative repro-
ductive cloning attempts suggests that
more groups and individuals will probably
pursue this goal as the technology
becomes simpler and more efficient in
animal models. Even without going so
far as cloning a person, the ability to
generate human sperm and, potentially
someday, oocytes from any somatic cell
raises a whole spectrum of ethical
tensions on the horizon, tensions for
which current legal systems appear to
be insufficiently prepared. These issue
include the prospect for infertile, lesbian,
and/or gay couples to have genetic chil-
dren through a combination of reprog-Cell Stem Ceramming stem cells into gametes and
modifying them with missing gender-
specific genes, which although already
discussed in the public arena, seems
unlikely from a biological point of view
(Mathews et al., 2009). Yet, although
such practices remain highly speculative
at present, the ongoing rapid progress in
the field and the lowering of regulatory
entry barriers increase the likelihood of
unforeseen new applications emerging.
The commodification of pluripotent
stem cells is not merely a convenient
metaphor; iPSCs are already giving rise
to a fledgling industry. Companies have
begun to market culture kits for human
iPSCs, and given the success, irrespec-
tive of utility, of private banks for the
storage of umbilical cord blood cells and
stem cells from deciduous teeth,
menstrual blood, peripheral blood, and
bone marrow, it is almost certain that
plans for a private iPSC bank are already
being laid. Indeed, when the Chinese
stem cell tourism company Beike
Biotechnology opened its Jiangsu Stem
Cell Storage Facility in mid-2008, the
company specifically cited its intent to
store human iPSCs in the future. This
trend by no means suggests that safe
and effective clinical applications for
these cells will soon become available,
only that when the value placed on pluri-
potency is combined with a readily
obtainable cell source and an unregulated
business environment, industry is sure to
follow. Given this eventuality and the
significant potential risks associated with
the transplantation of undifferentiated
pluripotent cells, competent authorities
will need to move quickly to develop
quality standards and mechanisms of
enforcement. Similarly, although I am not
aware of any clinics that offer to inject
iPSCs into patients willing to pay for
them, the success of the stem cell tourism
businesses that advertise other cell types
(Kiatpongsan and Sipp, 2009; Lau et al.,
2008) seems to guarantee that someone,
somewhere will give it a try (or at least
claim to), and such a possibility further
highlights the need for appropriate
protective measures given that many of
the technical and regulatory barriers that
previously restricted access to human
pluripotent cells have now been over-
come.
The plurality of methods now available
for the generation of human iPSCs alsoll 5, October 2, 2009 ª2009 Elsevier Inc. 361
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intellectual property claims will be made,
and valued, concerning methods for
inducing pluripotency. Should a single
patented method become dominant,
that patent would presumably be of
much greater value than a comparable
hESC patent (such as the fundamental
patents owned by the Wisconsin Alumni
Research Foundation and licensed to
Geron) because the potential user base
would be much broader, both for those
deriving new lines and even using existing
ones that fall under the patent’s domain.
Correspondingly, the existence of
multiple competing methods would
reduce the value of any given patent in
a similarly sized market. How the intellec-
tual property landscape is ultimately map-
ped is likely to remain in doubt pending
the development of one or more tech-
niques for induction by small molecules,
and legal tests of the strength of the re-
sulting patents. For now, the extant
patents on iPSC technologies remain
comparatively narrow and unchallenged
in court, and yet one could safely predict
that much remains to be seen regarding
the protection and commercialization of
iPSC derivation protocols and the cell
lines that are produced.
Business issues aside, research institu-
tions and support frameworks are already
struggling to readjust to the new reality of
pluripotency as a ‘‘cheap’’ and plentiful
commodity, rather than a scarce and
precious resource. Existing hESC cell
banks, including the U.S. National Stem
Cell Bank (www.nationalstemcellbank.
org/) and the cell bank at the RIKEN Bio-
Resource Center in Japan (http://www.
brc.riken.go.jp) have already begun to
bank iPSCs, and registries such as the
International Stem Cell Registry at the
University of Massachusetts (http://
www.umassmed.edu/iscr) and the E.U.’s
Human Embryonic Stem Cell Registry
(www.hescreg.eu) are beginning to
catalog existing human iPSC lines. But
now that some studies generate dozens
of new human iPSC lines, it is improbable
that any registry, let alone stem cell bank,
will be able to keep pace with output.
Indeed, many researchers may not see
the value of banking new lines or even
maintaining them; pluripotency has not
only become a commodity, it is becoming
a disposable one. Indeed, even with the
highly valued hESCs, some labs com-362 Cell Stem Cell 5, October 2, 2009 ª200plained of the costs in time, money, and
effort to fulfill the characterization and
pluripotency tests required to merit a full
listing in the more stringent registries. Of
course, there remains important value
in the public banking of well-character-
ized, standardized, and quality-controlled
human iPSC lines, and there is scope for
a bank of selected HLA-matched iPSCs
(Nakatsuji et al., 2008). However, should
a highly reproducible, safe, and efficient
method for their generation become avail-
able, human pluripotent cell lines are likely
to flood the field in unmanageable
numbers. This predicted trend raises the
same sorts of questions addressed by
Maherali and Hochedlinger, Daley et al.,
and Ellis et al., as mentioned above. In
the event that a strict standard for pluripo-
tency is adopted by the research commu-
nity, it is conceivable that a handful of
well-characterized, standardized, and
centrally banked iPSC lines could come
to dominate the field. Once again, if
a highly efficient, reproducible protocol
for generating iPSCs becomes available,
I predict that many labs would choose to
do the work of generating lines them-
selves, unless the intellectual property
landscape makes the ‘‘do-it-yourself’’
approach prohibitively expensive. In
either instance, individual researchers
are unlikely to spend as much time as
they have in the past on characterization
and the meticulous passaging of lines. It
also seems certain that human iPSCs
will be used with increasing frequency
by labs that previously did not work with
stem cells; in the not-so-distant future,
we may even witness the induction of plu-
ripotency as a high school science class
project.
The stem cell and reprogramming fields
are moving so quickly, in fact, that pluri-
potency itself may one day no longer be
seen as so necessary, and therefore so
valuable, as it is today. Early work by
Weintraub et al. (1989), along with more
recent successes in direct reprogram-
ming across lineages of differentiated
somatic cells (reviewed in Zhou and
Melton, 2008), highlight the first steps on
a road that may take pluripotency from
a coveted resource to a plentiful
commodity, to just one of many possible
routes toward the long-sought goal of
control over cellular identity. For this
reason, policy-setters should exercise
caution when developing their strategies9 Elsevier Inc.for the long term; it took less than 10 years
from the first derivation of human ESCs to
the first human iPSCs, but some countries
have already committed large sums to
10 year plans for the specific promotion
of the field of induced pluripotency at
a time when its future is far from certain.
There is ample precedent for the rapid
downward change in the unit value of
a resource or technology as related
resources become more accessible,
a trajectory that I would argue human
ESCs are already on. The predictions of
Moore’s Law and the related ‘‘Carlson
Curve,’’ which tracks the rapidly declining
costs of DNA synthesis, stand as testa-
ment to the transformational role played
by new technologies on the value of indi-
vidual instances of once-rare resources.
But perhaps the most apt (or at least the
most aesthetic) comparison can be
made with the modern mass production
of flawless and nearly indistinguishable
manmade diamonds for a minute fraction
of the value at which a similar natural dia-
mond could be sold. Speculative author
Neal Stephenson predicted such an even-
tuality in his novel The Diamond Age,
which itself was a fictional examination
of the transformational power of tech-
nology. The diamond industry is even
now fighting to maintain the market value
of their natural products by lobbying for
protective laws and developing detection
methods to discriminate one source from
another. Thus, both diamonds and plurip-
otent cells represent resources that were
scarce, as a result of a combination of
natural and social factors, and that are
on their way to becoming more plentiful,
less costly, and minimally problematic to
work with. As a result, both cases are
paving the way toward new innovations
and applications (synthetic diamonds,
for example, are already being studied
for potential uses in optics and elec-
tronics). Although the primary value of
human pluripotent stem cells has thus
far been perceptual rather than economic,
we too are faced with the need to reas-
sess the value of the old gold standards
now that we stand on the brink of our
own Diamond Age.
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